Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

425

Participants

Timeline

Start Date

December 31, 1998

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

BCG vaccine

BIOLOGICAL

autologous tumor cell vaccine

BIOLOGICAL

recombinant interferon alfa

DRUG

chemotherapy

DRUG

cyclophosphamide

Trial Locations (17)

10032

Herbert Irving Comprehensive Cancer Center, New York

19104

University of Pennsylvania Cancer Center, Philadelphia

19107

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia

29303

Palmetto Hematology/Oncology Associates, Spartanburg

30033

Georgia Cancer Specialists, Decatur

33180

Columbia - HCA Cancer Research Network, North Miami Beach

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

40202

James Graham Brown Cancer Center, Louisville

49546

Cancer and Hematology Centers of Western Michigan, Grand Rapids

55422

Hubert H. Humphrey Cancer Center, Robbinsdale

60068

Lutheran General Cancer Care Center, Park Ridge

60612

University of Illinois at Chicago, Chicago

64111

Midwest Oncology Consortium, Kansas City

92270

Cancer and Blood Institute of the Desert, Rancho Mirage

06520-8028

Yale Comprehensive Cancer Center, New Haven

07753

Jersey Shore Cancer Center, Neptune City

08901

Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AVAX Technologies

INDUSTRY

NCT00003715 - Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | Biotech Hunter | Biotech Hunter